Jeff Sternlicht: Why LDL-C and ApoB Remain King of the Hill?
Jeff Sternlicht, Emergency Physician and Medical Director at Vituity, shared a post on LinkedIn:
“In cardiovascular prevention, there’s one question more important than whether a biomarker predicts risk:
Does changing it improve outcomes?
Last week’s Lp(a)HORIZON results brought that question back into focus.
The trial did not meet its primary cardiovascular endpoint despite substantial lowering of Lp(a).
That matters.
But we should be equally careful about what it does not tell us.
This was one outcomes trial, testing one Lp(a)-lowering therapy in a specific population with established cardiovascular disease.
It did not prove that Lp(a) doesn’t matter. And it certainly did not prove that lowering Lp(a) will never reduce cardiovascular events.
The epidemiologic and genetic evidence linking elevated Lp(a) to ASCVD remains compelling. Other potent Lp(a)-lowering therapies and outcomes trials are still coming.
So for me, the appropriate conclusion is simple:
We still don’t know.
But HORIZON also reminds us just how high the evidentiary bar should be before a biomarker becomes a proven therapeutic target. And that is where LDL-C and ApoB remain king of the hill.
The evidence surrounding the apoB-containing lipoprotein pathway converges from almost every direction:
- Epidemiology.
- Genetics.
- Mendelian randomization.
- Randomized clinical trials.
- Multiple drug classes.
- Cardiovascular outcomes.
Again and again, the conclusion points in the same direction:
Lower exposure to apoB-containing lipoproteins, particularly earlier and for longer, means less atherosclerotic cardiovascular disease.
We measure many other biomarkers that provide important information about cardiovascular risk.
- Lp(a).
- Triglycerides.
- HDL-C.
- hsCRP.
- Homocysteine.
They are not equivalent, and their biology and evidence differ substantially.
Some may ultimately prove to be important therapeutic targets. Inflammation already has randomized evidence supporting specific therapeutic pathways. Lp(a) has particularly compelling genetic evidence and remains one of the most important unanswered questions in cardiovascular prevention.
But prediction, causality, and proven therapeutic benefit are different standards of evidence.
When a patient asks me today, ‘What can I actually change that has the deepest evidence for reducing my risk of atherosclerotic cardiovascular disease?’
I keep coming back to the same place:
Reduce exposure to apoB-containing lipoproteins.
And fortunately, we have more tools than ever to do it. Statins. Ezetimibe. PCSK9 monoclonal antibodies. Inclisiran. Bempedoic acid.
Different mechanisms. An extraordinary body of evidence pointing in the same direction.
There is still a lot to learn about Lp(a) and the other pathways driving residual cardiovascular risk. But today, LDL-C and ApoB remain king of the hill.
Views are my own and do not represent those of my employers or affiliates. For educational purposes only. This is not medical advice.”
Other posts featuring Jeff Sternlicht on Hemostasis Today.
-
Oct 27, 2026, 05:58Cedric Hermans: An Evening of Cinema in Support of Blood Disorder Research
-
Oct 27, 2026, 04:56Ayodeji Olayanju: Why Choose between a Transfusion and Haemoglobinopathy CPD When You Can Do Both?
-
Oct 27, 2026, 04:54Aisha Suala: When One Underfilled Tube Can Mislead the Entire Laboratory Result
-
Oct 27, 2026, 04:34Incremental Mobility and Venous Thromboembolism Risk in Hospitalized Medical Patients – JTH
-
Oct 27, 2026, 04:29Matthew Hazell: From Rare Blood to AI – Reflecting on Three Days of Innovation at AABB 2026
-
Oct 27, 2026, 04:24Khairul Missa Mohd Amin: Highlights from RANZCR ASM 2026 and Building Stronger PE Care
-
Oct 27, 2026, 04:14Pedro Perez: Why the Future of PE Care Demands Individualized Strategy
-
Oct 27, 2026, 04:09Hari Trivedi: Real-World AI Performance in PE Detection
-
Oct 27, 2026, 03:50Nathalie Conrad: Uncovering 30-Year Sex Differences Across 55 ESC Nations